"""
Question: 1101 

Evidence: This study allowed us to document the circulating HIV-1 subtypes in Suriname and present the first published data on TDR in HIV-1-infected individuals in Suriname. The genetic data obtained can serve as a baseline for Suriname to monitor emerging mutations.

Rationale: The paper explicitly states it presents the first published data on transmitted drug resistance in Suriname, indicating the data were previously unpublished. The mention of establishing a baseline further supports originality.

Answer: Yes
"""

"""
Question: 1102 

Evidence: The molecular epidemiologic profile of HIV-1 in Suriname was determined through protease (PR) and reverse transcriptase (RT) sequences obtained from HIV-1 strains collected from 100 drug-naive HIV-1-infected persons. The GenBank accession numbers for the sequences are KX390878 to KX390977.

Rationale: The text states that PR and RT sequences were obtained and provides GenBank accession numbers, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers.

Rationale: The methods describe clinical sampling and direct genotypic sequencing of PR and RT from patient plasma without any description of in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: Drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm version 25, updated in September 2015. Evidence of TDR was defined based on the WHO list for surveillance of drug resistance mutations.

Rationale: The paper used genotypic prediction algorithms rather than phenotypic in vitro susceptibility testing; there are no IC50/IC90 or phenotypic assay results reported.

Answer: No
"""

"""
Question: 2101 

Evidence: The GenBank accession numbers for the sequences are KX390878 to KX390977. Successful amplification was observed for 99 PR and 95 RT genes.

Rationale: The paper explicitly provides GenBank accession numbers associated with the sequenced isolates, confirming deposition of sequences.

Answer: Yes
"""

"""
Question: 2102 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The GenBank accession numbers for the sequences are KX390878 to KX390977.

Rationale: The accessions correspond to sequences generated from clinical samples (adults with HIV in Suriname), not laboratory strains.

Answer: Yes
"""

"""
Question: 2103 

Evidence: The GenBank accession numbers for the sequences are KX390878 to KX390977. Successful amplification was observed for 99 PR and 95 RT genes.

Rationale: The paper states the exact accession range for the sequenced isolates.

Answer: KX390878–KX390977
"""

"""
Question: 2202 

Evidence: Sequence analysis for the presence of DRMs in PR according to the French ANRS algorithm, version 25, revealed no major mutation conferring drug resistance. However, we detected one isolate carrying mutations L10V, G16E, M36I, D60E, and I62V, which confer a resistance to Atazanavir (ATV) and a possible resistance to Saquinavir (SQV).

Rationale: The paper lists specific mutations for individual isolates (e.g., the exact combination of mutations in particular samples), indicating that per-sample mutation lists are reported (also detailed in Table 3).

Answer: Yes
"""

"""
Question: 2301 

Evidence: HIV-1 Genetic Diversity and Drug Resistance Mutations Among Treatment-Naive Adult Patients in Suriname. Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs.

Rationale: Both the title and methods specify the species as HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Subtype determination revealed that most viruses were of subtype B (94.9%) in both PR and RT genomic regions, followed by B/D recombinants (5.1%). Phylogenetic analyses together with the CPR tool showed that all RT sequences (n = 95) clustered with subtype B. All, but five PR sequences were subtype B (95%). The five non-B PR sequences were assigned to the D subtype.

Rationale: The paper reports predominantly subtype B, with evidence of B/D recombination reflected by D subtype PR in five cases.

Answer: Subtype B and B/D recombinants (PR subtype D in five cases)
"""

"""
Question: 2303 

Evidence: The molecular epidemiologic profile of HIV-1 in Suriname was determined through protease (PR) and reverse transcriptase (RT) sequences. For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers.

Rationale: The study sequenced the protease and reverse transcriptase regions.

Answer: Protease (PR) and Reverse Transcriptase (RT)
"""

"""
Question: 2304 

Evidence: For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers. The PR and RT nucleotide sequences obtained were aligned using MEGA5 software with known group M reference sequences.

Rationale: PR and RT are components of the HIV-1 pol gene, so the study reports pol region sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. Participants included in this study were selected from the ambulatory care services of the four hospitals in the capital Paramaribo and the 10 largest healthcare centers of the Regional Health Services, which cater to the capital and surrounding areas.

Rationale: The samples originated from Paramaribo, Suriname and surrounding areas.

Answer: Suriname (Paramaribo and surrounding areas)
"""

"""
Question: 2402 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. In 2009, the national standard first-line treatment in Suriname consisted of the combination of Zidovudine (AZT), Lamivudine (3TC), and Nevirapine (NVP).

Rationale: The study period is explicitly stated as August–October 2009.

Answer: 2009
"""

"""
Question: 2502 

Evidence: The amplified products were sent to Beckman Coulter Genomics (www.cogenicsonline.com) for direct sequencing on both strands. Chromatograms were verified, analyzed, and interpreted using CEQ 2000XL software (Beckman Coulter, Inc., Fullerton, CA).

Rationale: “Direct sequencing on both strands” with chromatogram analysis indicates Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: The amplified products were sent to Beckman Coulter Genomics (www.cogenicsonline.com) for direct sequencing on both strands. Chromatograms were verified, analyzed, and interpreted using CEQ 2000XL software (Beckman Coulter, Inc., Fullerton, CA).

Rationale: The description matches Sanger sequencing; no next-generation sequencing (NGS) platform or methods are mentioned.

Answer: No
"""

"""
Question: 2504 

Evidence: The amplified products were sent to Beckman Coulter Genomics (www.cogenicsonline.com) for direct sequencing on both strands. For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers.

Rationale: The sequencing was performed directly on PCR products without mention of cloning, indicating no cloning prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: The amplified products were sent to Beckman Coulter Genomics (www.cogenicsonline.com) for direct sequencing on both strands. For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers.

Rationale: The approach described corresponds to population (bulk) Sanger sequencing, not single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: The amplified products were sent to Beckman Coulter Genomics (www.cogenicsonline.com) for direct sequencing on both strands. For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers.

Rationale: There is no mention of molecular cloning; direct sequencing was used.

Answer: No
"""

"""
Question: 2601 

Evidence: Plasma was separated and stored at −80°C until RNA extraction for viral load (VL) measurement and genotyping. RNA was isolated from 1 ml of plasma with the Nuclisens EasyMag, as recommended by the manufacturer.

Rationale: Sequencing was performed from plasma-derived RNA.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Plasma was separated and stored at −80°C until RNA extraction for viral load (VL) measurement and genotyping. RNA was isolated from 1 ml of plasma with the Nuclisens EasyMag, as recommended by the manufacturer.

Rationale: The methods only describe plasma RNA sequencing; there is no mention of PBMC-derived DNA/RNA sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: Successful amplification was observed for 99 PR and 95 RT genes. Amplification of both genes could be obtained for 94 samples.

Rationale: These counts reflect the number of plasma-derived sequences successfully obtained for each gene.

Answer: 99 PR sequences and 95 RT sequences (both genes for 94 samples)
"""

"""
Question: 2604 

Evidence: Plasma was separated and stored at −80°C until RNA extraction for viral load (VL) measurement and genotyping. RNA was isolated from 1 ml of plasma with the Nuclisens EasyMag, as recommended by the manufacturer.

Rationale: No PBMC sequencing was performed; all sequences were from plasma RNA.

Answer: 0
"""

"""
Question: 2605 

Evidence: The VL ranged from 25 to 10^6 copies/ml. One patient was excluded for genotyping due to a VL below 100 copies/ml.

Rationale: Detectable plasma viral loads indicate active HIV replication in the individuals from whom sequences were obtained.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Plasma was separated and stored at −80°C until RNA extraction for viral load (VL) measurement and genotyping. RNA was isolated from 1 ml of plasma with the Nuclisens EasyMag, as recommended by the manufacturer.

Rationale: Sequencing targeted plasma RNA, not proviral DNA, indicating sequences were not from the proviral DNA reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The mean age was 38 years (range, 18–62) for women and 39 (range, 23–58) for men.

Rationale: The study enrolled adults only, with age ranges confirming no infants/children.

Answer: No
"""

"""
Question: 2702 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study was approved by the Ministry of Health's National Ethics Committee.

Rationale: The design is observational (cross-sectional), not a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study was approved by the Ministry of Health's National Ethics Committee.

Rationale: Since this was not a clinical trial, it is not possible that all individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: One hundred one HIV-1-infected adult naive patients were recruited in Paramaribo. One patient was excluded for genotyping due to a VL below 100 copies/ml.

Rationale: After excluding one from genotyping, samples for sequencing were obtained from 100 individuals.

Answer: 100
"""

"""
Question: 3102 

Evidence: Successful amplification was observed for 99 PR and 95 RT genes. Amplification of both genes could be obtained for 94 samples.

Rationale: Not all individuals had successful sequencing of both genes; hence, not all underwent HIV sequencing.

Answer: No
"""

"""
Question: 4101 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The genotyping was performed as an additional diagnostic test for the study participants.

Rationale: The study explicitly sequenced viruses from ART-naive individuals.

Answer: Yes
"""

"""
Question: 4102 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: All participants were ARV-naive; no sequences from previously treated individuals were reported.

Answer: No
"""

"""
Question: 4103 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: The cohort was entirely ART-naive; there were no ART-experienced individuals.

Answer: No
"""

"""
Question: 4104 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. One hundred one HIV-1-infected adult naive patients were recruited in Paramaribo.

Rationale: All 101 samples were collected from ART-naive individuals.

Answer: 101
"""

"""
Question: 4105 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: The paper clearly states ARV-naive status for all participants, providing complete ART history status for the cohort.

Answer: Yes
"""

"""
Question: 4201 

Evidence: Analysis of drug resistance mutations showed only one transmitted dug resistance mutation (TDRM) (V75M) in a single strain. This study reveals that the HIV-1 epidemic in Suriname is still characterized by a low TDRM rate (1%).

Rationale: The paper quantifies the prevalence of transmitted drug resistance.

Answer: Yes
"""

"""
Question: 4202 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. According to the WHO list for surveillance of DRMs, the overall prevalence of TDR in Suriname was 1% with only one isolate bearing a DRM to the NRTI Stavudine.

Rationale: The study measures transmitted (pretreatment) resistance among ART-naive individuals, thus reporting pretreatment resistance prevalence.

Answer: Yes
"""

"""
Question: 4301 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: All participants were ARV-naive, so no drug classes were received by individuals in this study.

Answer: NA
"""

"""
Question: 4302 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers.

Rationale: There is no report of any individual receiving integrase inhibitors; the cohort was ARV-naive.

Answer: No
"""

"""
Question: 4303 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: No participants received protease inhibitors; they were all ARV-naive.

Answer: No
"""

"""
Question: 4304 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: Participants did not receive ART as they were ARV-naive; hence, they did not all receive the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: Being ARV-naive implies they had not received INSTIs, so they were INSTI-naive.

Answer: Yes
"""

"""
Question: 4403 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: As all were ARV-naive, none received more than one ART regimen.

Answer: 0
"""

"""
Question: 4404 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: As all were ARV-naive, none received more than two ART regimens.

Answer: 0
"""

"""
Question: 4405 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: All individuals received zero ART regimens, which is the same number for everyone.

Answer: Yes
"""

"""
Question: 4406 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: As all were ARV-naive, they did not receive one ART regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: Dolutegravir is an integrase inhibitor; since all participants were ARV-naive, none received dolutegravir.

Answer: 0
"""

"""
Question: 4502 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The study population consisted of ARV-naive adult HIV-1-positive persons living in Paramaribo and the surrounding areas with a CD4 count ≤385.

Rationale: Darunavir is a protease inhibitor; since all participants were ARV-naive, none received darunavir.

Answer: 0
"""

"""
Question: 5101 

Evidence: With regard to the presence of DRMs in RT, one isolate out of 95 (1.05%) exhibited a major DRM (V75M), conferring resistance to the NRTI Stavudine (d4T). According to the WHO list for surveillance of DRMs, the overall prevalence of TDR in Suriname was 1% with only one isolate bearing a DRM to the NRTI Stavudine.

Rationale: Using the WHO surveillance list for transmitted DRMs, only one individual had a drug resistance mutation.

Answer: 1
"""

"""
Question: 5102 

Evidence: For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers. The PR and RT nucleotide sequences obtained were aligned using MEGA5 software with known group M reference sequences.

Rationale: The study did not sequence the integrase gene and reported no INSTI resistance mutations.

Answer: 0
"""

"""
Question: 5103 

Evidence: With regard to the presence of DRMs in RT, one isolate out of 95 (1.05%) exhibited a major DRM (V75M), conferring resistance to the NRTI Stavudine (d4T). According to the WHO list for surveillance of DRMs, the overall prevalence of TDR in Suriname was 1% with only one isolate bearing a DRM to the NRTI Stavudine.

Rationale: The only reported NRTI DRM was V75M (confers d4T resistance); there is no mention of TDF (tenofovir) resistance mutations.

Answer: 0
"""

"""
Question: 5104 

Evidence: For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers. The PR and RT nucleotide sequences obtained were aligned using MEGA5 software with known group M reference sequences.

Rationale: Integrase was not sequenced and no INSTI resistance mutations were reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: Drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm version 25, updated in September 2015. Evidence of TDR was defined based on the WHO list for surveillance of drug resistance mutations.

Rationale: No phenotypic susceptibility testing was performed; only genotypic predictions were used.

Answer: NA
"""

"""
Question: 6102 

Evidence: Drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm version 25, updated in September 2015. Sequence analysis for the presence of DRMs in PR according to the French ANRS algorithm, version 25, revealed no major mutation conferring drug resistance.

Rationale: The paper does not report IC50 or IC90 values; it uses genotypic algorithms.

Answer: No
"""

"""
Question: 6103 

Evidence: Drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm version 25, updated in September 2015. According to the WHO list for surveillance of DRMs, the overall prevalence of TDR in Suriname was 1% with only one isolate bearing a DRM to the NRTI Stavudine.

Rationale: There are no IC50 fold change values reported; only genotypic resistance predictions and prevalence.

Answer: No
"""

"""
Question: 6104 

Evidence: Drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm version 25, updated in September 2015. Evidence of TDR was defined based on the WHO list for surveillance of drug resistance mutations.

Rationale: No phenotypic assay was used; thus, no specific phenotypic susceptibility assay is reported.

Answer: NA
"""

"""
Question: 6105 

Evidence: The molecular epidemiologic profile of HIV-1 in Suriname was determined through protease (PR) and reverse transcriptase (RT) sequences obtained from HIV-1 strains collected from 100 drug-naive HIV-1-infected persons. Drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm version 25, updated in September 2015.

Rationale: The study did not report replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: Drug susceptibility was predicted using the French ANRS HIV-1 genotypic drug resistance algorithm version 25, updated in September 2015. According to the WHO list for surveillance of DRMs, the overall prevalence of TDR in Suriname was 1% with only one isolate bearing a DRM to the NRTI Stavudine.

Rationale: No phenotypic drug susceptibility testing was performed, so no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. The amplified products were sent to Beckman Coulter Genomics for direct sequencing on both strands.

Rationale: The isolates are clinical and directly sequenced; there is no mention of site-directed mutagenesis.

Answer: No
"""

"""
Question: 7102 

Evidence: Between August and October 2009, a prospective cross-sectional study was conducted using plasma samples collected from 101 HIV-1-positive adults naive to ARV drugs. For genotyping, RNA was reverse transcribed to cDNA and amplified for partial RT and protease genes using the ANRS consensus sets of primers.

Rationale: The study did not perform in vitro passage experiments; it analyzed patient-derived sequences.

Answer: No
"""